Madrigal Pharmaceuticals: Upcoming Windfall Profits

Summary

• Like an early Christmas/Hanukkah present, Madrigal shares rallied over 268% in one session due to the positive MAESTRO-NASH data. The shares continue to move in the ensuing day.
• Coupled with the strong Phase 3 (MAESTRO-NAFLD-1) results, Madrigal is poised to file a marketing application in H1 next year.
• As resmetirom is poised to enter an untapped mega blockbuster market, you can expect windfall profits for Madrigal.

The most important quality for an investor is temperament, not intellect.?- Warren Buffett

After shares gap up following either a drug approval or a Phase 3 data release, they usually trade lower in the following days. Nevertheless, there is certain?equity that continues to rally due to extremely powerful fundamental developments. That is to say, if the aforesaid event would unlock the mega-blockbuster value of a lead drug, chances are that the stock would rally much higher.

Following robust MAESTRO-NASH for resmetirom (as I?forecasted),?Madrigal Pharmaceuticals?(NASDAQ:MDGL) stock continues to exchange hands much higher even after its meteoric rise. Precisely speaking, there is a good chance that Resmitirom would gain approval and thereby generate windfall profits. In this research, I'll feature a fundamental analysis of Madrigal while focusing on the latest corporate developments.

YOU CAN EITHER READ THE 1)?FREE ARTICLE?ON SEEKING ALPHA OR 2)?IN-DEPTH ANALYSIS?INSIDE INTEGRATED BIOSCI INVESTING.